Morgan Stanley
FTXH icon

Morgan Stanley’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Morgan Stanley’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
5,917
+1
+0% +$35 ﹤0.01% 5905
2026
Q1 		$203K Buy
5,916
+1
+0% +$34 ﹤0.01% 5860
2025
Q4 		$195K Sell
5,915
-1
-0% -$31 ﹤0.01% 5946
2025
Q3 		$169K Hold
5,916
– – ﹤0.01% 5951
2025
Q2 		$152K Buy
5,916
+1
+0% +$25 ﹤0.01% 5958
2025
Q1 		$163K Sell
5,915
-26
-0.4% -$720 ﹤0.01% 5822
2024
Q4 		$160K Sell
5,941
-1
-0% -$28 ﹤0.01% 5869
2024
Q3 		$171K Buy
5,942
+5,940
+297,000% +$170K ﹤0.01% 5807
2024
Q2 		$56 Hold
2
– – ﹤0.01% 7462
2024
Q1 		$71 Buy
2
+1
+100% +$28 ﹤0.01% 7410
2023
Q4 		$31 Buy
+1
New +$25 ﹤0.01% 7609
2022
Q1 		– Sell
-600
Closed -$16K – 8012
2021
Q4 		$16K Buy
+600
New +$15.8K ﹤0.01% 7299

Other funds holding FTXH

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
MIM
Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley's FTXH Position: Q2 2026 in Review

Morgan Stanley increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 0.02% in Q2 2026, buying an estimated $35 and bringing the position to 5,917 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #5905.

Morgan Stanley first reported a position in FTXH in Q4 2021 and has held it in 12 quarters since. 30 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

  • Morgan Stanley held 5,917 shares of First Trust Nasdaq Pharmaceuticals ETF worth $226K as of Q2 2026.
  • Morgan Stanley bought 1 First Trust Nasdaq Pharmaceuticals ETF share in Q2 2026, an estimated $35.
  • First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5905 holding.
  • Morgan Stanley first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2021 and has held it in 12 quarters since.
  • 30 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.